KHK2455

DRUG3 trials

Sponsors

Kyowa Kirin, Inc.

Conditions

CancerCarcinomaGlioblastoma MultiformeSolid TumorUrothelial Carcinoma

Phase 1

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

CompletedNCT02867007

Kyowa Kirin, Inc.Cancer, Carcinoma, Solid Tumor

Start: 2016-08-31End: 2019-12-15Updated: 2024-04-25

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

TerminatedNCT03915405

Kyowa Kirin, Inc.Urothelial Carcinoma

Start: 2019-09-26End: 2022-11-15Updated: 2024-04-25

Unknown Phase

Expanded Access for KHK2455

Kyowa Kirin, Inc.Glioblastoma Multiforme

Updated: 2024-04-25

Related Papers

First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

Cancer2025-06-194 citations

287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2020-11-013 citations

Abstract CT238: An open-label, phase 1 study of IDO inhibitor KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma

Cancer Research2020-08-151 citations

First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2018-05-2013 citations